SCHEMBL14413264

SCHEMBL14413264

Nc1ccc(/N=N/c2ccc(-c3ccc(S(=O)(=O)O)cc3)cc2)c2ccc(S(=O)(=O)O)cc12

nearest known ligand 0.88

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP2C9 P11712 1/20 0.88
▸ CYP2C19 P33261 1/20 0.88
▸ HSD17B10 Q99714 1/20 0.88
▸ PHLPP2 Q6ZVD8 2/20 0.86
▸ SLC7A11 Q9UPY5 1/20 0.67
▸ SENP2 Q9HC62 7/20 0.61
▸ SENP3 Q9H4L4 6/20 0.61
▸ SENP1 Q9P0U3 6/20 0.61
▸ SUMO2 P61956 5/20 0.61
▸ SUMO1 P63165 5/20 0.61
▸ SENP7 Q9BQF6 5/20 0.61
▸ ENPP2 Q13822 1/20 0.55
▸ GLO1 Q04760 4/20 0.49
▸ MEN1 O00255 1/20 0.48
▸ ALDH1A1 P00352 1/20 0.48
▸ APP P05067 1/20 0.48
▸ MAPT P10636 1/20 0.48
▸ THRB P10828 1/20 0.48
▸ HPGD P15428 1/20 0.48
▸ ALOX12 P18054 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14418368 0.99 CYP2C9 (0.90) CYP2C9CYP2C19HSD17B10PHLPP2SLC7A11
SCHEMBL2585430 0.96 CYP2C9 (0.81) CYP2C9CYP2C19HSD17B10PHLPP2SLC7A11
SCHEMBL2585427 0.96 CYP2C9 (0.81) CYP2C9CYP2C19HSD17B10PHLPP2SLC7A11
SCHEMBL12177913 0.95 CYP2C9 (0.79) CYP2C9CYP2C19HSD17B10PHLPP2SLC7A11
SCHEMBL2541491 0.94 CYP2C9 (1.00) CYP2C9CYP2C19HSD17B10PHLPP2SLC7A11
SCHEMBL2541489 0.94 CYP2C9 (1.00) CYP2C9CYP2C19HSD17B10PHLPP2SLC7A11
SCHEMBL12224760 0.93 PHLPP2 (1.00) CYP2C9CYP2C19HSD17B10PHLPP2SLC7A11
SCHEMBL12177898 0.92 CYP2C9 (0.76) CYP2C9CYP2C19HSD17B10PHLPP2SLC7A11
SCHEMBL12177917 0.92 CYP2C9 (0.75) CYP2C9CYP2C19HSD17B10PHLPP2SLC7A11
SCHEMBL2592899 0.91 CYP2C9 (0.73) CYP2C9CYP2C19HSD17B10PHLPP2SLC7A11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7264932-B2 Nuclease inhibitor cocktail APPLERA CORPORATION (US) 2007-09-04 — — US disclosed
US-7264932-B2 Nuclease inhibitor cocktail APPLERA CORPORATION (US) 2007-09-04 — — US disclosed
US-20070032418-A1 Small-molecule inhibitors of angiogenin and rnases and in vivo and in vitro methods of using same AMBION, INC (US) 2007-02-08 — — US disclosed
US-20070032418-A1 Small-molecule inhibitors of angiogenin and rnases and in vivo and in vitro methods of using same AMBION, INC (US) 2007-02-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070032418-A1 Small-molecule inhibitors of angiogenin and rnases and in vivo and in vitro methods of using same RNASE1, RNASEH1, RNASEL CYP2C9 4801/4885CYP2C19 4749/4885HSD17B10 2691/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback